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Abstract 
Chronic use of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) has repeatedly been 
associated with deficits in working memory, declarative memory, and executive functions. However, 
previous findings regarding working memory and executive function are inconclusive yet, as in most 
studies concomitant stimulant use, which is known to affect these functions, was not adequately 
controlled for. Therefore, we compared the cognitive performance of 26 stimulant-free and largely 
pure (primary) MDMA users, 25 stimulant-using polydrug MDMA users, and 56 MDMA/stimulant-
naïve controls by applying a comprehensive neuropsychological test battery. Neuropsychological tests 
were grouped into four cognitive domains. Recent drug use was objectively quantified by 6-month 
hair analyses on 17 substances and metabolites. Considerably lower mean hair concentrations of 
stimulants (amphetamine, methamphetamine, methylphenidate, cocaine), opioids (morphine, 
methadone, codeine), and hallucinogens (ketamine, 2C-B) were detected in primary compared to 
polydrug users, while both user groups did not differ in their MDMA hair concentration. Cohen’s d 
effect sizes for both comparisons, i.e., primary MDMA users vs. controls and polydrug MDMA users 
vs. controls, were highest for declarative memory (dprimary=.90, dpolydrug=1.21), followed by working 
memory (dprimary=.52, dpolydrug=.96), executive functions (dprimary=.46, dpolydrug=.86), and attention 
(dprimary=.23, dpolydrug=.70). Thus, primary MDMA users showed strong and relatively discrete 
declarative memory impairments, whereas MDMA polydrug users displayed broad and unspecific 
cognitive impairments. Consequently, even largely pure chronic MDMA use is associated with 
decreased performance in declarative memory, while additional deficits in working memory and 
executive functions displayed by polydrug MDMA users are likely driven by stimulant co-use. 
 
Keywords: cognition, entactogen, empathogen, MDEA, MDA, MDMA 
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1. Introduction 
With an estimated 18.8 million past-year users, 3,4-methylenedioxymethamphetamine (MDMA, 
“ecstasy”) remains one of the most used illicit drugs worldwide (United Nations Office on Drugs and 
Crime, 2016). MDMA is a synthetic substituted amphetamine derivate that blocks and reverses the 
monoamine transporters leading to a rapid release of monoamines, especially of serotonin (5-HT) but 
also of noradrenalin and dopamine (Kalant, 2001; Rudnick and Wall, 1992). In rodents and in non-
human primates, research found evidence for long-term loss of 5-HT nerve terminals (Commins et al., 
1987; Hatzidimitriou et al., 1999; Ricaurte et al., 1988). In humans, MDMA-related reductions of 5-
HT transporters in different regions of the basal ganglia and the neocortex have been reported 
analogously (for review see Roberts et al., 2016b). Over the past three decades, the behavioral effects 
of MDMA use have been investigated extensively, and a broad range of cognitive dysfunctions has 
been reported in long-term MDMA users (Parrott, 2013). 
While declarative memory impairments have been consistently shown in MDMA users with moderate 
to large effect sizes (for review see Kalechstein et al., 2007; Parrott, 2013), other cognitive domains 
yielded inconclusive results. The meta-analysis from Laws and Kokkalis (2007) found a medium 
effect size (d=0.63) for working memory (short-term memory) deficits in recreational MDMA users, 
but also reported that impairments are likely driven by verbal working memory deficits, whereas 
visual working memory may be primarily affected by cannabis use. On the other hand, working 
memory deficits found in the often applied (immediate) prose recall task (Morgan, 1999), which 
measures verbal working (immediate recall) and declarative memory (delayed recall), could not be 
replicated by all investigators (e.g., Thomasius et al., 2003; 2006). Moreover, a meta-regression over 
12 comparisons revealed that differences in immediate prose recall between MDMA users (or ex-
MDMA users) and controls are partially ascribable to the group’s unequal intelligence status (Rogers 
et al., 2009). For delayed recall tasks (declarative memory), the same bias was found, but, in contrast 
to working memory performance, differences between MDMA users and controls remained significant 
after controlling for intelligence status (Rogers et al., 2009).  
Regarding potential attention deficits in MDMA users, results seem to differ between studies 
investigating basic or higher order attention: Some studies examining basic attention or vigilance 
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reported no impairments (e.g., Back-Madruga et al., 2003; Parrott, 2013; Rodgers, 2000), in contrast to 
studies investigating higher order sustained attention that found strong impairments (Fox et al., 2001; 
McCann et al., 1999). However, in a meta-analytic review, Kalechstein (2007) reported only small to 
moderate effect sizes for attention/concentration deficits in MDMA users compared to matched 
controls. For executive functions, a recent meta-analysis by Roberts et al. (2016a) investigated four 
components of executive functions: inhibition, switching, updating (Miyake et al., 2000), and access 
(Fisk and Sharp, 2004) and found that – compared to non-MDMA polydrug using controls – polydrug 
MDMA users display significant alterations with a small effect size in all functions with exception of 
the unaffected inhibition component. However, the authors state that they cannot rule out the 
possibility that concomitant drug use contributed to the deficits found in executive functioning of the 
polydrug MDMA users. 
Inconsistencies and interpretation difficulties within findings for cognitive deficits in long-term 
MDMA users – especially regarding working memory and attention - are apparent and may be 
partially explained by different factors limiting the interpretation of results. Perhaps the most serious 
disadvantages of human MDMA research are that drug consumption is mostly measured via self-
reports (drug interviews) and that MDMA users often use other drugs (Schifano et al., 1998). 
Consequently, the interpretation of performance differences between MDMA users and controls in 
cross-sectional studies cannot be attributed solely to MDMA use (Curran, 2000). This is evident in 
experiments comparing polydrug MDMA users with drug-naïve controls, as possible long-term effects 
cannot be distinguished from the effects of other drugs. Also, in experiments with a non-MDMA 
polydrug control group, possible interaction effects between MDMA and other drugs may mask the 
pure effects of MDMA. Lastly, studies investigating non-polydrug MDMA users that do not 
quantitatively objectify (e.g., by toxicological hair testing) drug use remain unaware of the truth-value 
of the reported drug use patterns assessed with drug interviews. Because drug users might have 
different motivations to give a biased self-report or simply over- or underestimate their own 
consumption because of consistently shown memory alterations, we objectively quantified drug use 
through hair analyses in the present study. 
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To our knowledge, no study has investigated cognitive alterations in a sample of objectively 
confirmed pure MDMA users so far. Thus, we compared largely pure (in the following also called 
“primary” MDMA users) and polydrug MDMA users with drug-naïve healthy controls on well-
established cognitive tasks. Drug use during the last months was objectively determined by 
quantitative hair analyses for all participants. We hypothesized that largely pure MDMA users still 
show disturbed declarative memory functions with a strong effect size, whereas other cognitive 
domains are only slightly or moderately impaired. In contrast, we expect stimulant-using polydrug 
MDMA users to show additional impairments in working memory, executive functions and attention 
given that these cognitive domains have been shown to be affected by cocaine (Jovanovski et al., 
2005; Vonmoos et al., 2013; Vonmoos et al., 2014), amphetamine (Lundqvist, 2005), and 
methamphetamine use (Scott et al., 2007).  
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2. Experimental procedures 
2.1 Participants 
Within the context of the Zurich Cocaine Cognition Study (ZuCo2St), which has started in 2010 
(Quednow, 2016; Vonmoos et al., 2013), we recruited 53 long-term MDMA users and 56 drug-naïve, 
healthy controls by means of flyer and online media advertisements. Prior to testing, candidates 
underwent a brief telephone screening to assess their study eligibility. All subjects had to be aged 
between 18 and 60 years and had to have sufficient German language skills. Based on the results of 
the hair analyses (see below), 25 MDMA users were classified as polydrug MDMA users, 26 were 
classified as primary MDMA users and 2 MDMA users were excluded because of deficient/missing 
hair samples. Participants were categorized as primary MDMA users only if their hair analyses 
revealed MDMA consumption and the hair cocaine and amphetamine concentrations – the most 
common co-used drugs in our sample – did not exceed the cut-off values of 500pg/mg or 200pg/mg 
respectively (Cooper et al., 2012). Based on these cut-off values, we consequently classified 
participants as polydrug MDMA users if their amphetamine or cocaine hair concentrations exceeded 
these values and MDMA metabolites were detected (see Table 1 and Supplementary Table S1). This 
enabled us to compare 26 stimulant-free, primary MDMA users with 25 stimulant-using polydrug 
MDMA users, and 56 drug-naïve healthy controls. The groups were matched for age, sex, verbal 
intelligence, years of education, depression scores, and cannabis consumption during the past half year 
(Table 2).  
The general exclusion criteria encompassed current or previous neurological disorders or head injuries, 
any clinically significant medical disease, a family history of schizophrenia or bipolar disorder, the 
prescription of drugs affecting the central nervous system, and a lifetime history of opioid use. 
Additionally, all participants who reported daily cannabis consumption were excluded. Controls were 
also excluded if they fulfilled the diagnostic criteria for any Axis-I DSM-IV psychiatric disorder 
including any form of addiction (except nicotine), or if they reported current or previous regular illegal 
drug use (except cannabis). Exclusion criteria for the MDMA groups were any acute or previous Axis-
I DSM-IV adult psychiatric disorders with the exception of MDMA, alcohol, and nicotine misuse and a 
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history of depression (acute major depression was excluded). Inclusion criteria for the MDMA group 
were MDMA use of at least 100 occasions or weekly consumption during the last year, and a current 
abstinence period of less than 6 months. 
All participants were asked to abstain from illegal substances for at least three days and from alcohol 
for at least 24h prior to testing. Drug urine screenings controlled for compliance (see below). The 
Cantonal Ethics Committee of Zurich has approved the study, and all participants gave written 
informed consent. The participants were compensated for their participation with 180 Swiss Francs.  
 
2.2 Assessment measures 
2.2.1 Clinical Assessment 
Trained psychologists conducted the Structured Clinical Interview for Axis-I DSM-IV disorders in 
order to exclude participants with an Axis-I DSM-IV psychiatric disorder. Depressive symptoms were 
assessed with the Beck Depression Inventory (BDI) (Beck et al., 1961). Severity of ADHD symptoms 
was evaluated with the ADHD self-rating scale (ADHD-SR) corresponding to DSM-IV criteria (Rosler 
et al., 2004). Premorbid verbal intelligence was estimated with a German vocabulary test 
(Mehrfachwahl-Wortschatz-Intelligenztest) (Lehrl et al., 1995).  
2.2.2 Drug use Assessment 
Self-reported drug use was assessed with the Interview for Psychotropic Drug Consumption 
(Quednow et al., 2004). In addition, to objectively quantify the participant’s drug use, hair samples 
were taken from the posterior vertex region of the head in order to determine the concentration of 17 
common drugs and their metabolites by liquid chromatography-tandem mass spectroscopy (Cooper et 
al., 2012). To exclude intoxication at testing, urine drug screenings were employed by semi-
quantitative enzyme multiplied immunoassay (see Supplementary Methods S1 for technical details).  
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2.2.3 Assessment of cognitive performance 
Cognitive performance was assessed with four tests from the Cambridge Neuropsychological Test 
Automated Battery (Strauss et al., 2006): Rapid Visual Information Processing, Spatial Working 
Memory, Intra/Extra-Dimensional Set Shifting, and Paired Associates Learning. Furthermore, a 
German version of the Rey Auditory Verbal Learning Test (Helmstaedter et al., 2001) and the Letter 
Number Sequencing Task were administered (Wechsler, 1997). As previously published (Vonmoos et 
al., 2013; 2014), 15 predefined test parameters were z-transformed based on means and standard 
deviations of the control group and combined into four cognitive domains (Goldstein et al., 2004; 
Jovanovski et al., 2005; Pace-Schott et al., 2008; Vonmoos et al., 2013; Woicik et al., 2009): attention, 
working memory, declarative memory, and executive functions (see Supplementary Methods S3 for 
further details).  
2.3 Statistical Analysis 
We performed the statistical analyses with SPSS 22.0 for Windows. Demographic and drug use data 
for all groups were analyzed with Pearson’s chi-square test and analyses of variance (ANOVA). To 
investigate group differences over all groups in cognitive parameters, we performed a multiple linear 
regression with the dummy coded (zero, 1) group variables as independent variables. To compare 
controls to the MDMA user groups, controls were chosen as the reference group, whereas for the 
comparison of the two MDMA using groups, polydrug MDMA users were coded 0 (Fig. 1 and Table 
3). To be able to assess the practical significance of cognitive performance differences between 
controls and the MDMA using groups, Cohen’s d effect sizes were calculated based on the means and 
pooled standard deviations (SD) of the two groups being compared (Cohen, 1988). Finally, we 
conducted multiple regression analyses (forced entry) to investigate the relationship between 
preselected predictors (age, sex, verbal IQ, grouping variables, BDI score and ADHD-SR score) and 
declarative memory performance. Further, multiple regression analyses were conducted over the 
MDMA users only to investigate possible factors influencing declarative memory performance in 
MDMA users; Model 1 estimated memory performance through drug use patterns covering the past 
six months (hair analyses and drug use per week) and in Model 2, estimations were based on drug use 
variables describing the duration of use or cumulative lifetime dose. Based on an à priori power 
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analysis with G*Power 3.1.9.2 (Faul et al., 2007) (Linear multiple regression: Fixed model, single 
regression coefficient, f2=0.15, α= 0.05, two predictors), this study has an alpha-error probability of 
5% and a power of over 85%.  
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3. Results 
3.1 Demographic Characteristics and Drug Use 
For demographic parameters, the groups did not differ significantly in age, verbal IQ, years of 
education, sex distribution, and depression scores (Table 2). For age, the middle 50% of all 
participants were aged between 22 and 29 years, while the youngest participant was 18 and the oldest 
47 years old. However, both MDMA groups differed from controls with regard to their ADHD-SR 
scores. For objective drug-use measures, polydrug and primary MDMA users had significantly higher 
MDMA hair drug concentrations than controls but did not differ from each other. Importantly, only 
polydrug MDMA users differed from controls in amphetamine, cocaine and ketamine hair 
concentrations, whereas primary MDMA users only showed minimal exposure to these drugs (for 
detailed hair analyses of all MDMA users see Table 1). For cannabis, amphetamine, and cocaine, 
primary MDMA users showed no significant differences regarding positive urine tests compared to 
controls, while the polydrug MDMA user group contained three cocaine-positive urine analyses. 
Primary MDMA users did not differ significantly from controls in any tobacco, alcohol, and cannabis 
measure, while polydrug MDMA users reported stronger current smoking and drinking habits. 
 
3.2 Cognition 
Significant regression equations with the dummy coded group variables were found for all four z-
transformed domains of attention (F(2,104)=4.591, p<.05), working memory (F(2,104)=9.584, 
p<.001), declarative memory (F(2,104)=21.187, p<.001), and executive functions (F(2,104)=7.297, 
p<.01). Group differences between controls and polydrug MDMA users were significant for all four 
domains (p<.01-.001), whereas group differences between controls and primary MDMA users only 
reached significance for working memory (p<.05) and declarative memory (p<.01) performance 
(Table 3). Effect sizes for performance differences over the four domains are shown in Figure 1. For 
polydrug MDMA vs. controls, working memory, declarative memory and executive functions reached 
large effect sizes (d=0.96, 1.21, and 0.86 respectively), while attention difficulties reached a moderate 
to large effect size (d=0.70). For the comparison of primary MDMA users and controls, only 
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declarative memory impairments reached a large effect size (d=0.90), whereas working memory as 
well as executive functions displayed moderate and attention only small effect sizes. Accordingly, for 
the single cognitive parameters depicted in Figure 2, only comparisons between polydrug MDMA 
users and controls reached large effect sizes of 0.8 and higher. For primary MDMA users vs. controls, 
the largest effect sizes were found for verbal (RAVLT) and visuo-spatial (PAL) declarative memory 
measures.  
3.3 Regression models 
To analyze potential cofactors and dose-response effects on declarative memory performance multiple 
regression analyses were performed. These analyses over all participants (n=106) for demographic 
variables (age, sex, and verbal IQ) and group contrasts revealed that being either a primary or a 
polydrug MDMA user significantly decreases the intercept of the regression equation of declarative 
memory performance (β=-.232, t=-2.76, p<.01, and β=-.508, t=-5.97, p<.001). As expected, the 
significant coefficients for age and verbal IQ were negative and positive respectively. The regression 
model was significant (R2=0.37, F5, 105=11.753, p<.001). The model only explained 2.1% more 
variance after adding the BDI and the ADHD-SR sum score in a second step (p=.183) (Supplementary 
Table S2). Neither of the two variables predicted declarative memory performance significantly 
(p=.101 and p=.130).  
The association between declarative memory performance and drug use parameters was assessed with 
two models covering either the past six month (Model 1) or lifetime substance use (Model 2) of the 
MDMA users (n=51). Model 1 contained the following variables: cannabis consumption in grams per 
week, the amount of cigarettes smoked per day, amount of alcohol consumed per week, MDMA hair 
concentration, and a grouping variable that differentiated between primary and polydrug MDMA users 
to account for stimulant use (Supplementary Table S3). None of the drug parameters predicted 
declarative memory performance. However, the grouping variable showed that polydrug substance use 
decreased the intercept (t=-1.93, p=.059, β=-.279). 
Model 2, which contained drug use parameters concerning lifetime drug consumption, revealed that – 
within MDMA users – lifetime cannabis consumption predicted declarative memory performance 
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(p<.05) when duration of alcohol and nicotine use and lifetime MDMA consumption were held 
constant (Supplementary Table S4).  
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4. Discussion 
The aim of the study was to investigate the cognitive performance of objectively verified, primary and 
largely pure MDMA users. Detailed psychiatric diagnostics, hair toxicology, and an exact matching 
procedure minimized the influence of psychiatric comorbidities and underreported drug use. We 
demonstrated that primary and polydrug long-term MDMA users show medium to strong cognitive 
impairments in declarative memory and that, in contrast to polydrug MDMA users, primary MDMA 
users show only small and moderate impairments in the domains of attention, working memory, and 
executive functions compared with drug-naïve controls. The data of this study confirm previously 
shown memory deficits in abstinent long-term MDMA users and thus deliver evidence for declarative 
memory impairments even in largely pure recreational MDMA users with no or minimal stimulant co-
use.  
 
In line with previous meta-analyses (Kalechstein et al., 2007; Laws and Kokkalis, 2007; Rogers et al., 
2009), our data show that the strongest impairments have to be expected in declarative memory 
functions after repeated MDMA consumption, which confirms our hypothesis. Task-specifically, 
decreased delayed verbal memory performance (RAVLT) can be considered the “main symptom” of 
MDMA misuse as the variable delayed recall has been repeatedly shown to differentiate between 
MDMA users and controls (Fox et al., 2001; Quednow et al., 2006; Reneman et al., 2000) and 
revealed the strongest effect size in this study for polydrug MDMA users as well as for primary 
MDMA users. In line with previous findings (Laws and Kokkalis, 2007), effect sizes for verbal 
memory deficits were larger than for visual memory deficits in MDMA users. Regarding the PAL 
measures, our data are in accordance with previous studies showing that polydrug MDMA users 
required more trials to complete the task compared to polydrug controls (Fox et al., 2002). Taken 
together, the individual variables of our declarative memory domain indicate moderate to large 
impairments (d=0.62-1.1) in visual, spatial and verbal learning and recognition processes.  
Regarding working memory deficits, the primary MDMA users performed worse than controls on the 
domain level only with a medium effect size (d=0.52), whereas polydrug MDMA users showed strong 
working memory impairments (d=0.96). This discrepancy in performance may explain the 
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inconsistencies in previous findings and underline the additional detrimental effect of stimulant use on 
working memory (Vonmoos et al., 2013; 2014). Interestingly, primary MDMA users did not differ 
substantially from controls in two out of three measures for working memory, LNST score and total 
errors in the SWM task. Both measures are widely accepted measures for working memory 
performance (Crowe, 2000; Morris et al., 1988) and have previously been linked to MDMA-induced 
deficits (Fox et al., 2002; 2005). Our data do not replicate these findings for largely pure MDMA users 
but support our hypothesis that working memory deficits in polydrug MDMA users are likely 
stimulant-driven, and consequently, that past findings may be explained by undetected stimulant co-
consumption. It is noteworthy that – although our working memory domain differentiated significantly 
between controls and primary MDMA users – only the underlying first trial memory score (PAL) 
reached significance. This variable was viewed as a measure for passive storage ability and has shown 
to correlate stronger with verbal than with non-verbal memory parameters, probably because subjects 
verbalize the patterns and/or places which have to be remembered (Torgersen et al., 2012). In the 
context of Fox et al.’s (2001) suggestion that verbal learning problems in MDMA users are associated 
with storage and retrieval problems, and the finding that MDMA use affects verbal memory more 
strongly than visual memory, it can be argued that working memory performance between primary 
MDMA users and controls might in sum be less impaired then our working memory domain suggests 
at a first glance. Alternatively, the moderate working memory impairment displayed by our primary 
MDMA user group might be a result of past stimulant consumption, which may have occurred before 
the time span captured by the hair analyses. This idea is supported by a significant negative correlation 
between working memory performance and self-reported lifetime cocaine consumption across all 
MDMA users (r(49)=-.40, p<.01).  
For primary MDMA users, we did not find any significant results in the domains of executive 
functions and attention except for the RAVLT parameter recall consistency, which contrasts with 
previous studies that found executive function and decision-making impairments in MDMA users 
(Fisk and Montgomery, 2009; Fisk et al., 2004; Montgomery et al., 2005; Quednow et al., 2007; 
Roberts et al., 2016a). On the other hand, Montgomery et al. (2005) – who investigated the executive 
functions specifically – found no impairments in MDMA users compared to controls in switching, 
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which is – besides updating – tested by the Intra-Extra Dimensional Set Shift Task (IED) applied in 
the present study. In line with Montgomery et al. (2005) we did not find changes in the IED 
performance in primary MDMA users. Interestingly, the only variable assessing executive functions 
that reached significance (recall consistency, RAVLT) strongly involves verbal memory in contrast to 
the other, non-significant variables involving visual memory processes. As mentioned before, results 
vary regarding attentional performance of MDMA users, which is also reflected in our results; in all 
three parameters measuring attention, the polydrug MDMA users performed significantly worse than 
controls with moderate effect sizes, whereas primary MDMA users did not differ substantially from 
controls. These results are in line with previous research as 1) stimulant users were shown to perform 
worse than drug-naïve controls in an equally created attention domain (Vonmoos et al., 2013), and 2) 
as basic attentional and executive functions are generally unaffected in MDMA users compared to 
polydrug or cannabis using control groups (Medina et al., 2005; Parrott, 2001; Rogers et al., 2009). 
Interestingly, in contrast to our polydrug MDMA users, largely pure cocaine users did not differ from 
stimulant-naïve controls in the RAVLT supraspan in a previous study from our lab (Vonmoos et al., 
2013). Future research should therefore investigate possible interaction effects of MDMA and 
stimulant consumption more in depth, especially because animal studies revealed that the 
simultaneous administration of MDMA (or MDMA analogues) and a prodopaminergic agent leads to 
a potentiation of the serotonin neurotoxicity of MDMA (Clemens et al., 2005; Johnson et al., 1991; 
Johnson and Nichols, 1991; Schmidt et al., 1991).  
 
The results of our regression analysis for demographic variables support the notion of declarative 
memory deficits in abstinent primary MDMA users, as group contrasts remained significant even 
when sex, age, and verbal IQ were held constant. By adding the BDI and ADHD-SR sum core, the 
model only improved marginally. We have previously investigated the effects of depression and 
ADHD symptoms on cognitive performance in cocaine users and found that both factors, ADHD and 
depression scores, were associated with worse cognitive performance in cocaine users (Vonmoos et 
al., 2013; Wunderli et al., 2016). We therefore expected to find significant contributions of these two 
variables in the regression model again. However, probably due to the relative small variance in BDI 
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and ADHS-SR scores and the matching process (exclusion of psychiatric disorders), declarative 
memory was not significantly predicted through these two measures.  
Model 1, which predicted declarative memory performance through drug use parameters covering the 
past six months, revealed no significant associations except for the grouping variable that 
distinguished between primary and polydrug MDMA users. Although this grouping variable only 
predicted declarative memory performance by trend (p=.059), the importance of stimulant co-
consumption is emphasized by the fact that polydrug MDMA users displayed higher – although none 
significantly higher – mean values in all of the other predictors. 
In Model 2, declarative memory performance was aimed to be predicted by factors covering 
cumulative lifetime drug use estimates. Although the whole model predicted declarative memory 
performance by trend only, it revealed that the estimated lifetime dose of cannabis was negatively 
associated with memory performance. Additionally, the grouping variable still predicted memory 
performance with constant drug factors by trend. It was postulated previously that cognitive deficits in 
MDMA users can be explained by cannabis co-use alone (Croft et al., 2001). Our data do not support 
this assumption because the two user groups still differ in declarative memory performance when the 
effect of cannabis consumption is held constant. This finding is therefore in line with previous studies 
demonstrating memory deficits in MDMA users, even when concomitant cannabis use was introduced 
as a covariate or when MDMA users were compared to cannabis using controls (Fox et al., 2001; 
Quednow et al., 2006). However, our results support the notion that cannabis is an important confound 
when cognitive performance is measured in MDMA users (Croft et al., 2001; Simon and Mattick, 
2002), although the cannabis use intensity was relatively low in our sample.  
Finally, in both models, severity of MDMA consumption did not predict declarative memory 
performance (MDMA hair concentration and lifetime dose). Previous literature is inconclusive about 
the correlation between MDMA dose and strength of impairments. Many researchers reported dose-
related impairments in MDMA users (Bolla et al., 1998; Gouzoulis-Mayfrank et al., 2000; 
Montgomery et al., 2005; Quednow et al., 2006). These findings were usually interpreted as evidence 
for selective, neurotoxic effects on the 5-HT system (Gouzoulis-Mayfrank et al., 2003; Parrott, 2002; 
Quednow et al., 2006; Quednow et al., 2004). On the other hand, Laws and Kokkalis (2007) found no 
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continuous relationship of lifetime MDMA consumption of MDMA and memory measures in their 
meta-analysis and therefore proposed a rather stepwise relationship between MDMA use and memory 
decline. This explanation is in line with a recent, longitudinal study that only found marginally 
significant changes in recall measures in stimulant-using polydrug MDMA users over a 2 year period 
(Wagner et al., 2015). Because neither MDMA hair concentrations nor self-reported amount of 
lifetime MDMA consumption significantly predicted memory performance, our data support this 
model of a stepwise relationship between MDMA use and memory decline. Moreover, also duration of 
abstinence did not predict memory performance in our sample (β=.010, t=0.70, p=.945). An alternative 
explanation of these discrepancies may lie in the variability of the purity of MDMA tablets potentially 
leading to different results across studies (Morgan, 1999; Parrott, 2004). In fact, recent analyses in the 
context of the Swiss Drug Checking program showed that only 7.1% of the ecstasy samples (n=210) 
tested in 2016 contained psychoactive substances other than MDMA (see 
http://www.saferparty.ch/125.html). 
This study has some limitations. First, human MDMA research practice was criticized for applying 
unreliable self-reported drug assessments (Cole, 2014). Although we objectively quantified 
participants drug use via hair analyses, we had to rely on participants self-reports for alcohol, nicotine, 
and cannabis consumption. Obviously, in a sample in which memory deficits can be expected, self-
reported drug assessment might be less reliable. Nonetheless, we aimed to minimize the influence of 
these drugs by matching the groups accordingly. Second, there is the possibility that cognitive 
differences are based on pre-existing differences and that predispositions are responsible for drug use 
and cognitive impairments. This limitation can be controlled by adding a polydrug control group. 
However, the present investigation is a cross-sectional study that is not suitable to differentiate 
between predisposing factors and drug-induced alterations. 
 
Taken together, our data suggest that the combined use of MDMA and stimulants is associated with a 
strongly increased risk for cognitive impairments compared to primary MDMA consumption and that 
the pronounced working memory and executive function impairments in polydrug MDMA users are 
likely driven by stimulant co-use. However, primary MDMA users showed robust and strong 
18 
 
 
alterations of declarative long-term memory. The considerable performance difference of primary vs. 
polydrug MDMA users together with the finding that cannabis additionally impairs memory 
performance in MDMA users highlights the need for objective group assessments in human MDMA 
research. Future research should therefore distinguish between stimulant using and primary MDMA 
users while the influence of other drugs of abuse but especially cannabis consumption should be either 
excluded or controlled for by matching or an additional cannabis-only user group. 
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Table 1: Hair analyses parameters for all groups. 
 Controls (n=56) Primary MDMA (n=26) Polydrug MDMA (n=25) 
MDMA    
Hair analysis pg/mgd 0.00 (0.00) 3414 (9184) 4894 (5398) 
Min / max hair value 0.00 / 0.00 32 / 48000 134 / 17500 
N > 0 0 26 25 
MDEA    
Hair analysis pg/mgd 0.00 (0.00) 7.5 (23.64) 12.96 (31.54) 
Min / max hair value 0.00 / 0.00 0 / 114 0 / 145 
N > 0 0 4 6 
MDA    
Hair analysis pg/mgd 0.00 (0.00) 90.15 (79.68) 187.96 (247.2) 
Min / max hair value 0.00 / 0.00 0 / 331 0 / 1088 
N > 0 0 25 23 
Amphetamine    
Hair analysis pg/mg 0.00 (0.00) 38.5 (63.8) 801.0 (1804) 
Min / max hair valuen 0.00 / 0.00 0 / 195 0 / 8324 
N > 0 0 9 17 
Methamphetamine    
Hair analysis pg/mgd 0.00 (0.00) 0.00 (0.00) 42.2 (152.04) 
Min / max hair value 0.00 / 0.00 0.00 / 0.00 0 / 730 
N > 0 0 0 3 
Cocaine    
Hair analysis pg/mg 0.00 (0.00) 63.8 (111.5) 3893 (5554) 
Min / max hair value 0.00 / 0.00 0 / 445 73 / 24500 
N > 0 0 10 25 
MPH    
Hair analysis pg/mgd 0.00 (0.00) 0.00 (0.00) 3.98 (17.93) 
Min / max hair value 0.00 / 0.00 0 / 0 0 / 98.5 
N > 0 0 0 2 
Morphine    
Hair analysis pg/mgd 0.00 (0.00) 0.00 (0.00) 8 (40) 
Min / max hair value 0.00 / 0.00 0 / 0 0 / 200 
N > 0 0 0 1 
Codeine    
Hair analysis pg/mgd 0.00 (0.00), n=32 0.00 (0.00), n=3 106.11 (307.24), n=9 
Min / max hair value 0.00 / 0.00 0 / 0 0 / 925 
N > 0 0 0 2 
Methadone    
Hair analysis pg/mgd 0.00 (0.00) 0.00 (0.00) 2.4 (12) 
Min / max hair value 0.00 / 0.00 0 / 0 0 / 60 
N > 0 0 0 1 
2C-B    
Hair analysis pg/mgd 0.00 (0.00), n=10 4.4 (15.4), n=25 11 (24.56), n=11 
Min / max hair value 0.00 / 0.00 0 / 63 0 / 65 
N > 0 0 2 2 
Ketamine    
Hair analysis pg/mgd 0.00 (0.00), n=10 13.26 (52.86), n=23 89.8 (127.52), n=10 
Min / max hair value 0.00 / 0.00 0 / 250 0 / 380 
N > 0 0 2 5 
 
Means, standard deviations, minimum and maximum for metabolites (pg/mg) are shown. If hair analyses were not available 
for some participants, sample size n for participants with hair analyses is shown. The cocaine metabolites benzoylecgonine, 
cocaethylene, and norcocaine are not shown. Tramadol and 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene (EDDP) are 
not shown because they were not detected.  
EDDP, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene; MDA, 3,4-Methylendioxyamphetamine; MDEA, 3,4-
Methylendioxy-N-ethylamphetmanine; MDMA, 3,4-Methylendioxy-N-methylamphetmanine; 2C-B, 2,5-dimethoxy-4-
bromphenethylamine.  
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Table 2: Demographic data and drug use (means and standard deviations) 
  Controls Primary MDMA Polydrug MDMA value p df 
        
n  56 26 25 
   
Age, years 25.8 (6.1) 26.6 (7.0) 26.7 (5.8) 0.25 0.78 2 
Years of school education 11.02 (1.6) 10.5 (1.8) 10.2 (1.9) 2.14 0.12 2 
Verbal intelligence 103.9 (8.2) 102.8 (8.3) 100.9 (8.3) 1.15 0.32 2 
Beck’s Depression Inventory score 3.5 (3.8) 4.4 (4.8) 5.2 (4.9) 1.29 0.28 2 
ADHD-SR score  7.7 (5.1) 12.8 (8.5)** 11.76 (7.7)* 6.57 0.00 2 
ADHD (y/n)a 0/56 3/23 4/21 8.64 .01 2 
Sex (female/male) 26/30 15/11 9/16 2.41 0.30 2 
  
      
Tobacco 
      
Smoking status (y/n)b 41/15 18/8 24/1*# 6.53 0.04 2 
Cigarettes per dayb 7.3 (10.1) 5.6 (8.2) 11.8 (7.6)*# 3.30 0.04 2 
Years of use 6.0 (6.6) 4.5 (6.1) 8.8 (5.6)# 3.05 0.05 2 
  
      
Alcohol 
      
Grams per weekb 117.9 (132.0) 138.1 (119.6) 184.3 (126.5)* 2.33 0.10 2 
Years of use 8.7 (6.5) 6.6 (7.1) 8.1 (5.7) 0.99 0.37 2 
  
      
Cannabis 
      
Status (y/n)b 30/26 19/7 15/10 2.81 0.25 2 
Grams per weekb 0.44 (1.04) 0.60 (1.3) 0.67 (1.4) 0.35 0.70 2 
Years of use 3.3 (3.7) 4.4 (5.1) 4.5 (4.5) 0.90 0.41 2 
Cumulative dose (grams) 195.7 (504.6) 543.1 (962.8) 767.4 (1153)* 4.69 0.01 2 
Positive urine testing (n/y)c,d 48/7 21/5 21/4 0.60 0.74 2 
Last consumption (days) 23.1 (32.9) n=30 18.0 (36.1) n=19 12.7 (23.3) n=15 0.55 0.58 2 
Last consumption (range, days)e 3 / 111 3 / 152 3 / 91    
  
      
MDMA 
      
Tablets per weekb,f 0.00 (0.00) 0.91 (0.89)*** 0.8 (1.1)*** 23.07 0.00 2 
Years of use 0.00 (0.00) 3.4 (3.2)*** 3.6 (2.5)*** 41.64 0.00 
 
Cumulative dose (grams) 0.13 (0.04) 26.6 (32.3)*** 21.0 (30.2)*** 17.66 0.00 2 
Last consumption (days) - 25.9 (21.4) n=26 43.0 (79.1) n=20 1.12 0.30 1 
Last consumption (range, days)e - 4 / 98 4 / 365    
  
      
Amphetamine 
      
Status (y/n)b 0/56 12/14*** 18/7*** 50.00 0.00 2 
Dependence (y/n)a 0/56 26/0 23/2 6.69 0.04 2 
Grams per weekb 0.00 (0.00) 0.01 (0.02) 0.11 (0.14)***### 22.93 0.00 2 
Years of use 0.00 (0.00) 1.9 (3.3)*** 2.2 (2.9)*** 12.34 0.00 2 
Last consumption (days) - 34.1 (44.3) n=12 27.6 (25.2) n=18 0.26 0.61 1 
Last consumption (range, days)e - 3 / 122 5 / 91    
Cumulative dose (grams) 0.01 (0.03) 35.0 (129.6)* 26.0 (57.9) 2.79 0.07 2 
Positive urine testing (n/y)c,d 55/0 26/0 24/1 3.27 0.20 2 
  
      
Cocaine 
      
Status (y/n)b 0/56 10/16*** 22/3***### 65.05 0.00 2 
Dependence (y/n)a 56/0 26/0 23/2 6.69 0.04 2 
Grams per weekb 0.00 (0.00) 0.03 (0.08) 0.62 (0.72)***### 29.35 0.00 2 
Years of use 0.00 (0.00) 1.4 (3.1)* 4.9 (4.3)***### 32.36 0.00 2 
Last consumption (days)  - 33.8 (40.9) n=10,  9/57 19.2 (23.5) n=22, 5/22 1.65 0.21 1 
Last consumption (range, days)e - 4 / 122 3 / 91    
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Cumulative dose (grams) 0.02 (0.05) 41.1 (162.3) 198.4 (259.1)***### 15.60 0.00 2 
Positive urine testing (n/y)c,d 55/0 26/0 22/3* 10.00 0.01 2 
       
Ketamin       
Status (y/n)b 0/56 2/24 6/19*** 14.40 0.00 2 
Last consumption (days) - 60.0 (17.0) n=2 244 (257.8) n=6 - - - 
Last consumption (range, days)e - 14 / 21 5 / 196    
Cumulative occasions 0.00 (0.00) 1.31 (3.98) 
 
2.86 (5.17) 
 
7.26 0.00 2 
 
Significant p-values (p<.05) are shown in bold. Statistical tests: ANOVA (all groups), χ2 test (all groups) for frequency data or 
independent t test (two groups).  
ADHD, attention-deficit/hyperactivity disorder; 
Consumption per week, duration of use, and cumulative dose are averages within the total group. 
Last consumption is an average only for persons who reported to have used the drug within the past 6 months. In this case, sample 
size (n) is shown. 
aAccording to DSM-IV criteria. 
bDuring the past 6 months. 
cFor cut-offs, see the Supplementary Methods S2. 
dOne urine sample (control) was missing. 
emin / max 
fIn 100-mg tablets. 
Post-hoc tests vs. controls: *p <.05, ** p <.01, ***p <.001; vs. primary MDMA # p <.05, ## p <.01, ### p <.001.
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Table 3: Cognitive parameters and domain scores. 
        
Controls vs. 
primary 
MDMA 
Controls vs. 
polydrug 
MDMA 
Primary vs. 
polydrug 
MDMA  
Cognitive parameters 
and domain scores 
Controls 
Primary 
MDMA 
users 
Polydrug 
MDMA 
users 
p p p 
n 56 26 25 
Attention 0.00 (0.78) -0.19 (0.86) -0.61 (0.95) .350 .003 .074 
RAVLT Supraspan trial 1 9.6 (2.6) 8.8 (2.0) 7.9 (2.4) .182 .003 .152 
RVP Discrimination 
performance A' 
0.92 (0.04) 0.92 (0.05) 0.90 (0.05) .575 .023 .135 
RVP Total hits 18.8 (4.3) 18.3 (5.0) 16.4 (5.1) .652 .040 .162 
Working memory 0.00 (0.60) -0.36 (0.79) -0.7 (0.9) .034 .000 .064 
LNST Score 15.9 (3.1) 15.2 (2.8) 13.8 (2.1) .356 .008 .126 
SWM Total errorsa 15.6 (12.2) 17.9 (15.7) 22.8 (16.4) .498 .040 .222 
PAL First trial memory 
score 
16.9 (2.6) 15.1 (3.4) 14.2 (3.1) .011 .000 .248 
Memory 0.00 (0.76) -0.77 (0.81) -1.7 (1.8) .004 .000 .003 
RAVLT Learning 
performance 
64.8 (6.0) 60.8 (5.4) 56.4 (8.3) .011 .000 .040 
RAVLT Delayed recall 14.0 (1.5) 12.7 (1.6) 11.4 (2.5) .004 .000 .029 
RAVLT Recognition 
performance adj. 
0.91 (0.08) 0.86 (0.07) 0.8 (0.2) .038 .001 .202 
PAL Total trials adj. 7.2 (1.5) 8.3 (2.2) 10.1 (3.7) .046 .000 .014 
PAL Total errors adj. 5.6 (4.3)  9.5 (7.0) 17.8 (19.0) .106 .000 .008 
Executive functions 0.00 (0.66) -0.36 (0.96) -0.81 (1.2) .093 .000 .073 
RAVLT Recall 
consistency (%) 
94.7 (4.6) 90.6 (5.4) 86.6 (8.9) .005 .000 .033 
SWM Strategy scorea 31.7 (5.4) 30.5 (6.1) 33.7 (4.1) .378 .127 .041 
IED Total trials adj. 97.2 (49.9) 36.7 (44.6) 44.1 (54.9) .243 .060 .525 
IED Total errors adj. 26.3 (28.7) 116.4 (76.4) 131.0 (95.3) .273 .086 .581 
Significant p-values (p<.05) are shown in bold. Statistical tests: Multiple linear regression with the dummy coded factors 
controls vs. primary MDMA users and controls vs. polydrug MDMA users (t-test) or polydrug MDMA users vs. controls 
and polydrug MDMA users vs. primary MDMA users. 
IED, Intra-Extra Dimensional Set Shift Task; LNST, Letter Number Sequencing Task; PAL, Paired Associates Learning; 
RAVLT, Rey Auditory Verbal Learning Test; RVP, Rapid Visual Information Processing; SWM, Spatial Working Memory.  
a Data of one participant (polydrug MDMA) are missing due to a technical failure.  
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Figure Captions  
Figure 1: Cohen’s d effect sizes for primary and polydrug MDMA users vs. controls over the cognitive domains. 
Significant dummy coded group contrasts of controls (n=56) vs. primary MDMA users (n=26): *p<.05, **p<.01; vs. 
polydrug MDMA users (n=25): ##p<.01, ###p<.001 are shown.  
 
Figure 2: Cohen’s d effect sizes for primary and polydrug MDMA users vs. controls over single parameters. 
Significant dummy coded group contrasts of controls (n=56) vs. primary MDMA users (n=26): *p<.05, **p<.01; vs. 
polydrug MDMA users (n=25): #p<.05, ##p<.01, ###p<.001 are shown.  
IED, Intra-Extra Dimensional Set Shift Task; LNST, Letter Number Sequencing Task; PAL, Paired Associates Learning; 
RAVLT, Rey Auditory Verbal Learning Test; RVP, Rapid Visual Information Processing; SWM, Spatial Working Memory.  
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Methods S1: Urine and hair toxicology 
Urine toxicology analyses comprised the following substances: tetrahydrocannabinol, cocaine, 
amphetamines, benzodiazepines, opioids, and methadone and were assessed by a semi-quantitative 
enzyme multiplied immunoassay method using a Dimension RXL Max (Siemens, Erlangen, Germany). 
For the detection of illegal drug use, the following cut-offs have been applied (Bush, 2008): Cannabis, 50 
ng/ml; cocaine, 150 ng/ml; and amphetamines, 500 ng/ml.  
To objectively characterize drug use over the last six months, hair samples were collected and analyzed 
with liquid chromatography-tandem mass spectrometry (LC-MS/MS). The proximal hair segment of a 
length of up to 6 cm was examined. The following 17 compounds were assessed: cocaine, 
benzoylecgonine, cocaethylene, norcocaine, amphetamine, methamphetamine, MDMA, MDEA, MDA, 
morphine, codeine, methadone, EDDP (primary methadone metabolite, 2-ethylidene-1,5-dimethyl-3,3-
diphenylpyrrolidene), tramadol, 2C-B, ketamine, and methylphenidate.  
For our routine protocol for drugs of abuse analysis a three-step washing procedure with water (2 minutes 
shaking, 15ml), acetone (2min., 10ml) and finally hexane (2min., 10ml) of hair was performed. Then the 
hair samples were dried at ambient temperatures, cut into small snippets and extracted in two steps, first 
with methanol (5ml, 16 hours, ultrasonication) and a second step with 3 ml MeOH acidified with 50 µL 
hydrochloric acid 33 % (3 hours, ultrasonication). The extracts were dried and the residue reconstituted 
with 50 µL MeOH and 500 µL 0.2 mM ammonium formate (analytical grade) in water. As internal 
standards deuterated standards of the following compounds were used, added as mixture of the following 
compounds: cocaine-d3, benzoylecgonine-d3, ethylcocaine-d3, morphine-d3, MAM-d3, codeine-d3, 
dihydrocodeine-d3, amphetamine-d6, methamphetamine-d9, MDMA-d5. MDEA-d6, MDA-d5, 
methadone-d9, EDDP-d3, methylphenidate-d9, tramadol-d3, oxycodone-d3, and ephedrine-d3. All 
deuterated standards were from ReseaChem (Burgdorf, Switzerland), the solvents for washing and 
extraction were of analysis grade and obtained from Merck (Darmstadt, Germany); LC-solvents were of 
HPLC grade and were obtained from Sigma Aldrich (Buchs, Switzerland). 
The LC-MS/MS apparatus was an ABSciex QTrap 3200 (Analyst software Version 1.5, Turbo V ion 
source operated in the ESI mode, gas 1, nitrogen (50 psi); gas 2, nitrogen (60 psi); ion spray voltage, 
3500V; ion source temperature, 450°C; curtain gas, nitrogen (20 psi) collision gas, medium), with a 
Shimadzu Prominence LC-system (Shimadzu CBM 20 A controller, two Shimadzu LC 20 AD pumps 
including a degasser, a Shimadzu SIL 20 AC autosampler and a Shimadzu CTO 20 AC column oven, 
Shimadzu, Duisburg, Germany). Gradient elution was performed on a separation column (Synergi 4µ 
POLAR-RP 80A, 150x2.0 with a POLAR-RP 4x2.0 Security Guard Cartridge, (Phenomenex, 
Aschaffenburg, Germany). The mobile phase consisted of 1mM ammonium formate buffer adjusted to pH 
3,5 with formic acid (eluent A) and acetonitrile containing 1mM ammonium formate and 1 mM formic 
acid (eluent B). The analysis was performed in MRM mode with two transitions per analyte and one 
transition for each deuterated internal standard, respectively. According to the Society of Hair Testing 
(Society of Hair, 2004), the following cut-offs have been applied: cocaine, 500 pg/mg; amphetamine, 200 
pg/mg; and MDMA, 200 pg/mg. 
 
Methods S2: Construction of cognitive domain scores 
Fifteen predefined main cognitive test parameters were z-transformed on the basis of means and standard 
deviations of the control group as published before (Vonmoos et al., 2013). If necessary, test scores were 
reversed so that high scores always indicated a better cognitive performance. These parameters were 
reduced to the four cognitive domains attention, working memory, declarative memory, and executive 
function. Furthermore, these four z-scored domains were equally integrated into a broad global cognitive 
index (GCI).  
Attention: To assess attentional capacity, we focused primarily on sustained attention by including the two 
Rapid Visual Information Processing (RVP) parameters discrimination performance A’ and total of hits 
3 
(Jones et al., 1992). In order to diversify this domain we added the Ray Auditory Verbal Learning Test 
(RAVLT) parameter trial 1, a supraspan measure with a large attentional component (Lezak et al., 2004).  
Working Memory: The Spatial Working Memory (SWM) parameter number of total errors tested the 
capability to retain spatial information and to manipulate remembered items in working memory (Morris 
et al., 1988). The Letter Number Sequencing Test (LNST) measured the verbal working memory by 
summing up the number of correct responses (Wechsler, 1997). The third parameter was the number of 
correctly located patterns after the first presentation, a Paired Associates Learning (PAL) parameter 
measuring primarily a visual working memory component (Sahakian et al., 1988). 
Declarative memory: The RAVLT was administered to assess the verbal declarative memory 
performance (Helmstaedter et al., 2001). Performance was measured by the parameters learning 
performance (∑trials 1-5), delayed recall (trial 7), and an adjusted recognition performance (p(A)) 
(Helmstaedter et al., 2001). To capture the visual declarative memory, we used the two PAL parameters: 
adjusted total of errors and adjusted total of trials (Sahakian et al., 1988). 
Executive Functions: The Intra/Extra-Dimensional Set Shifting Task (IED) assessed visual 
discrimination, attentional set formation, maintenance, shifting, and flexibility (Downes et al., 1989). The 
considered test parameters were the total of errors and trials adjusted to the amount of completed stages. 
Hereby, we added the SWM strategy score assessing the applied heuristic strategies (Morris et al., 1988), 
and the RAVLT recall consistency, a parameter impaired in patients with prefrontal lesions (Alexander et 
al., 2003; Benedict et al., 2005; Jokeit et al., 1997) and related with measures of executive functions 
(Beebe et al., 2000). 
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Table S1: Hair analyses results (concentration values in pg/mg) and MDMA group allocation.  
Subject 
Hair 
sample 
taken? 
MDMA group MDMA MDEA MDA Amphet-
amine 
Methamphet-
amine Cocaine 
Methyl-
phenidate 
Morphine/
Codeine 
Methadone/
EDDP 2C-B Ketamine 
Hair 
length1 
1 yes primary 1985 0 55 0 0 445 0 0 0 0 n.a. 6 
2 yes primary 975 0 30 55 0 45 0 0 0 n.a. n.a. 6 
3 yes primary 48000 40 150 60 0 80 0 0 0 0 n.a. 3.5 
4 yes primary 1673 0 102 0 0 0 0 0 0 47 0 6 
5 yes primary 915 0 45 59 0 156 0 0 0 0 0 2 
6 yes primary 780 21 50 0 0 169 0 0 0 0 0 6 
7 yes primary 4813 0 244 25 0 0 0 0 0 0 0 6 
8 yes primary 2239 0 121 0 0 0 0 0 0 0 0 3.5 
9 yes primary 2982 0 165 0 0 298 0 0 0 63 0 6 
10 yes primary 1440 0 60 122 0 0 0 0 0 0 0 3.5 
11 yes primary 626 0 41 0 0 0 0 0 0 0 0 6 
12 yes primary 2408 114 117 160 0 0 0 0 0 0 0 6 
13 yes primary 1763 0 125 15 0 0 0 0 0 0 0 6 
14 yes primary 1054 0 60 191 0 78 0 0 0 0 250 6 
15 yes primary 231 0 6 0 0 0 0 0 0 0 0 6 
16 yes primary 1369 0 67 0 0 0 0 0 0 0 0 4 
17 yes primary 2510 20 79 0 0 0 0 0 0 0 0 6 
18 yes primary 534 0 9 0 0 0 0 0 0 0 0 6 
19 yes primary 4670 0 331 0 0 81 0 0 0 0 0 6 
20 yes primary 2695 0 182 0 0 0 0 0 0 0 0 6 
21 yes primary 471 0 29 0 0 87 0 0 0 0 0 6 
22 yes primary 2232 0 55 0 0 0 0 0 0 0 55 6 
23 yes primary 32 0 5 0 0 0 0 0 0 0 0 6 
24 yes primary 2625 0 119 195 0 0 0 0 0 0 0 6 
25 yes primary 118 0 0 0 0 0 0 0 0 0 0 6 
26 yes primary 123 0 9 0 0 219 0 0 0 0 0 6 
27 yes poly 17500 0 750 180 0 7700 0 0 0 n.a. n.a. 6 
5 
28 yes poly 10659 43 266 755 0 73 0 0 0 0 191 1.5 
29 yes poly 14863 31 317 0 0 2515 0 0 0 0 174 5 
30 yes poly 2298 54 117 93 0 713 0 0 0 0 0 6 
31 yes poly 754 0 50 0 0 7233 0 0 0 0 0 1.5 
32 yes poly 12639 22 144 0 0 803 0 0 0 0 0 6 
33 yes poly 6050 0 303 8324 245 4243 0 0 0 0 31 6 
34 yes poly 15731 29 1088 4228 0 1178 0 0 0 65 0 6 
35 yes poly 1778 0 116 540 0 1583 0 0 0 0 122 6 
36 yes poly 134 0 0 808 0 88 0 0 0 56 0 6 
37 yes poly 146 0 0 1013 0 216 0 0 0 0 380 6 
38 yes poly 4650 0 195 730 0 24500 0 30 0 n.a. n.a. 6 
39 yes poly 2000 0 30 140 0 1000 0 0 0 n.a. n.a. 1.5 
40 yes poly 1200 0 20 0 0 2000 0 0 0 n.a. n.a. 3 
41 yes poly 1150 0 100 325 0 1275 0 0 0 n.a. n.a. 6 
42 yes poly 850 0 50 0 0 2800 0 0 0 n.a. n.a. 6 
43 yes poly 3150 0 215 105 730 590 0 0 0 n.a. n.a. 6 
44 yes poly 835 0 15 0 0 2900 0 925 0 n.a. n.a. 6 
45 yes poly 6350 0 307.5 0 80 1750 0 0 0 n.a. n.a. 6 
46 yes poly 1000 0 35 0 0 3300 0 200 60 n.a. n.a. 1.5 
47 yes poly 3750 145 150 1850 0 15000 0 0 0 n.a. n.a. 6 
48 yes poly 10000 0 250 440 0 10000 0 0 0 n.a. n.a. 1.5 
49 yes poly 2050 0 65 230 0 3450 0 0 0 n.a. n.a. 6 
50 yes poly 570 0 48 210 0 480 10 0 0 n.a. n.a. 2.5 
51 yes poly 2265 0 67.5 55 0 1950 89.5 0 0 n.a. n.a. 4 
52 no none n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 0 n.a. n.a. - 
53 no none n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 0 n.a. n.a. - 
 
For each participant, the amount of metabolites per substance (pg/mg) and the group are shown. The cocaine metabolites benzoylecgonine, cocaethylene, and norcocaine are not 
shown. Tramadol is not shown because it was not detected. Reasons for polydrug MDMA classification are shown in bold. 
To be included into the primary MDMA group, hair samples had to reveal a cocaine value <500pg/mg and an amphetamine value <200pg/mg (Cooper et al., 2012). 
1 analyzed hair length from scalp in cm.  
EDDP, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene; MDA, 3,4-Methylendioxyamphetamine; MDEA, 3,4-Methylendioxy-N-ethylamphetmanine; MDMA, 3,4-Methylendioxy-N-methylamphetmanine; n.a., not 
available; 2C-B, 2,5-dimethoxy-4-bromphenethylamine. 
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Table S2: Multiple Regression analysis for demographic variables, group contrasts and 
psychopathology predicting memory performance.  
 
  B SE B β 
Step 2 
   
Constant -.191 .229 
 
primary MDMA vs. Controls -.828 .271 -.270** 
poly MDMA vs. Controls -1.603 .268 -.523*** 
Sex -.041 .214 -.016 
Age -.041 .018 -.194* 
Verbal IQ .037 .013 .232** 
BDI sum score -.045 .027 -.150 
ADHD sum score .028 .018 .148 
 
Dependent variable: declarative memory performance (z-score). 
N = 106 (26 primary MDMA users, 25 poly MDMA users, and 56 controls).  
R2 = .37 and F = 11.753 (p<.001) for Step 1, ΔR2 = .021 and ΔF = 1.726 (p = .183) for Step 2. 
The data met the assumption of independent errors (Durbin-Watson value = 2.13). 
ADHD = Attention Deficit / Hyperactivity Disorder, ADHD sum score = Sum of Items 1 to 18, B = regression coefficient, β = standardized 
Beta, BDI = Beck’s Depression Inventory, SE B = standard error. 
Age is centered at the overall mean age (26.21 years) and verbal IQ is centered at 100 IQ points. Females were coded with 1 and males with 
0 for the sex variable.  
* p <.05, ** p <.01, *** p <.001 
 
 
Table S3: Multiple Regression analysis for drug use variables covering consumption over the 
past half year predicting memory performance. 
 
  B SE B β 
Constant 11.415 6.388 
primary MDMA vs. poly MDMA -.810 .419 -.279(*) 
Cannabis (g/week) -.232 .152 -.208 
Nicotine (cigarettes per day) -.039 .026 -.224 
Alcohol (g/week) .001 .002 .108 
MDMA hair concentration (pg/mg) .000 .000 .213 
 
Dependent variable: declarative memory performance (z-score). 
N = 51 (26 primary MDMA users, 25 poly MDMA users).  
R2 = .21 and F = 2.372 (p=.054). 
The data met the assumption of independent errors (Durbin-Watson value = 2.55). 
B = regression coefficient, β = standardized Beta, g/week = grams per week, pg/mg = picogram per milligram, SE B = standard 
error. 
Poly MDMA users were coded with 1 and primary MDMA users with 0 for the group comparison.  
(*) p =.059, 
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Table S4: Multiple Regression analysis for drug use variables covering consumption over the 
lifetime predicting memory performance. 
 
  B SE B β 
Constant 11.232 6.498 
primary MDMA vs. poly MDMA -.773 .423 -.266(*) 
Alcohol (years of use) -.018 .035 -.080 
Nicotine (years of use) -.016 .039 -.067 
Cannabis lifetime dose (g) -.000 .000 -.271* 
MDMA lifetime dose (tablets1) -.000 .001 -.011 
 
Dependent variable: declarative memory performance (z-score). 
N = 51 (26 primary MDMA users, 25 poly MDMA users).  
R2 = .19 and F = 2.103 (p=.083). 
The data met the assumption of independent errors (Durbin-Watson value = 2.40). 
B = regression coefficient, β = standardized Beta, g = grams, SE B = standard error. 
1 tablets à 100mg 
Poly MDMA users were coded with 1 and primary MDMA users with 0 for the group comparison.  
(*) p =.075, *p=.052 
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